Perioperative management of patients on chronic antithrombotic therapy

Blood

Volumn 120, Issue 24, 2012, Pages 4699-4705

  Ortel, Thomas L ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; DABIGATRAN; DIPYRIDAMOLE; EDOXABAN; ELINOGREL; ENOXAPARIN; EPTIFIBATIDE; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PHENPROCOUMON; PRASUGREL; RIVAROXABAN; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; TICLOPIDINE; TIROFIBAN; TRANEXAMIC ACID; WARFARIN;

ASSAY; ATHEROSCLEROSIS; BLEEDING; CARDIOVASCULAR SURGERY; CATARACT EXTRACTION; CORONARY ARTERY BYPASS SURGERY; CORONARY STENT; DRUG HALF LIFE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; LOW RISK POPULATION; NEUROSURGERY; PERCUTANEOUS CORONARY INTERVENTION; PERIOPERATIVE PERIOD; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROSTHETIC VALVE THROMBOSIS; REVIEW; STENT THROMBOSIS; SURGICAL RISK; THROMBIN TIME; THROMBOCYTE FUNCTION; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS; TOOTH EXTRACTION; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM;

EID: 84867308289     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-05-423228     Document Type: Review

References (43)

1. Douketis JD, Spyropoulos AC, Spencer FA, et al, American College of Chest Surgeons. Perioperative management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [erratum appears in Chest. 2012;141(4):1129]. Chest. 2012;141(Suppl 2):e326S-e350S.
2. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence Based Clinical Practice Guidelines (8th Ed). Chest. 2008;133(Suppl 6):160S-198S.
3. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood. 2010;115(1):15-20.
4. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Ed). Chest. 2008;133(Suppl 6):141S-159S.
5. Kearon C, Harrison L, Crowther M, Ginsberg JS. Optimal dosing of subcutaneous unfractionated heparin for the treatment of deep vein thrombosis. Thromb Res. 2000;97(6):395-403.
6. Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Ed). Chest. 2008;133(Suppl 6):199S-233S.
7. Husted S, van Giezen JJJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther. 2009;27(4):259-274.
8. Angiolillo DJ, Bhatt DL, Gurbel PA, Jennings LK. Advances in antiplatelet therapy: agents in clinical development. Am J Cardiol. 2009;103(Suppl 3):40A-51A.
9. Li C, Hirsh J, Xie C, Johnston MA, Eikelboom JW. Reversal of the anti-platelet effects of aspirin and clopidogrel. J Thromb Haemost. 2012;10(4):521-528.
10. Garcia DA, Regan S, Henault LE, et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med. 2008;168(1): 63-69.
11. Wysokinski WE, McBane RD, Daniels PR, et al. Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation. Mayo Clin Proc. 2008;83(6):639-645.
12. Douketis JD. Perioperative management of patients who are receiving warfarin therapy: an evidence-based and practical approach. Blood. 2011;117(19):5044-5049.
13. Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation. 2004;110(16):2287-2292.
14. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e419S-e494S.
15. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med. 1997;336(21):1506-1511.
16. Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous thrombosis. Lancet. 2010;376(9757):2032-2039.
17. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation. 1994;89(2):635-641.
18. Kaatz S, Douketis JD, Zhou H, Gage BF, White RH. Risk of stroke after surgery in patients with and without chronic atrial fibrillation. J Thromb Haemost. 2010;8(5):884-890.
19. Tafur AJ, McBane IIR, Wysokinski WE, et al. Predictors of major bleeding in peri-procedural anticoagulation management. J Thromb Haemost. 2012;10(2):261-267.
20. Omran H, Bauersachs R, Rubenacker S, Goss F, Hammerstingl C. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNK Online bRiDging rEgistRy (BORDER). Thromb Haemost. 2012;108(1):65-73.
21. Syed S, Adams BB, Liao W, Pipitone M, Gloster H. A prospective assessment of bleeding and international normalized ratio in warfarin-anticoagulated patients having cutaneous surgery. J Am Acad Dermatol. 2004;51(6):955-957.
22. Jamula E, Anderson J, Douketis JD. Safety of continuing warfarin therapy during cataract surgery: a systematic review and meta-analysis. Thromb Res. 2009;124(3):292-299.
23. White RH, McKittrick T, Hutchinson R, Twitchell J. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med. 1995;122(1):40-42.
24. Steib A, Barre J, Mertes M, et al. Can oral vitamin K before elective surgery substitute for preoperative heparin bridging in patients on vitamin K antagonists? J Thromb Haemost. 2010;8(3):499-503.
25. Barcellona D, Vannini ML, Fenu L, Balestrieri C, Marongiu F. Warfarin or acenocoumarol: which is better in the management of oral anticoagulants? Thromb Haemost. 1998;80(6):899-902.
26. Fihn SD, Gadisseur AAP, Pasterkamp E, et al. Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon. Thromb Haemost. 2003;90(2): 260-266.
27. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med. 2004;164(12):1319-1326.
28. Kovacs MJ, Kearon C, Rodger M, et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation. 2004;110(12):1658-1663.
29. Woods K, Douketis JD, Kathirgamanathan K, Yi Q, Crowther MA. Low-dose vitamin K to normalize the international normalized ratio prior to surgery in patients who require temporary interruption of warfarin. J Thromb Thrombolysis. 2007;24(2):93-97.
30. Dunn AS, Spyropoulos A, Turpie AG. Bridging therapy in patients on long-term anticoagulants who require surgery: the Prospective Perioperative Enoxaparin Cohort Trial (PROSPECT). J Thromb Haemost. 2007;5(11):2211-2218.
31. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116-1127.
32. Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012; 119(13):3016-3023.
33. Hillarp A, Baghaei F, Fagerberg Blixter I, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost. 2011;9(1):133-139.
34. Samama MM, Contant G, Spiro TE, et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost. 2012;107(2):379-387.
35. Hall R, Mazer CD. Antiplatelet drugs: a review of their pharmacology and management in the perioperative period. Anesth Analg. 2011;112(2):292-318.
36. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation. 2007;115(6):813-818.
37. Price MJ. Monitoring platelet function to reduce the risk of ischemic and bleeding complicatons. Am J Cardiol. 2009;103(Suppl 3):35A-39A.
38. Ceppa DP, Welsby IJ, Wang TY, et al. Perioperative management of patients on clopidogrel (Plavix) undergoing major lung resection. Ann Thorac Surg. 2011;92(6):1971-1976.
39. Savonitto S, D'Urbano M, Caracciolo M, et al. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth. 2010;104(3):285-291.
40. Angiolillo DJ, Firstenberg MS, Price MJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery. A randomized controlled trial. JAMA. 2012;307(3):265-274.
41. Thiele T, Sumnig A, Hron G, et al. Platelet transfusion for reversal of dual antiplatelet therapy in patients requiring urgent surgery: a pilot study. J Thromb Haemost. 2012;10(5):968-971.
42. O'Donnell M, Kearon C. Perioperative management of oral anticoagulation. Cardiol Clin. 2008; 26(2):299-309.
43. Thakur NA, Czerwein JK, Butera JN, Palumbo MA. Perioperative management of chronic anticoagulation in orthopaedic surgery. J Am Acad Orthop Surg. 2010;18(12):729-738.